Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

Inclusion Criteria: * Haemophilia A or B * Bodyweight max 100 kg * Body Mass Index (BMI) max 30 kg/m2 * Adequate venous access Exclusion Criteria: * Known or suspected allergy to trial product(s) or related products (including NovoSeven®) * The receipt of any investigational product within 30 days prior to enrolment in this trial * Receipt of Immune Tolerance Induction (ITI) within the last 1 month prior to participation in this trial * The receipt of any haemostatic treatment for control of a bleeding episode within the last 5 days prior to administration of trial product * Receipt of FVIII or FIX replacement therapy within 48 hours prior to trial product administration * Known pseudo tumours * Congenital or acquired coagulation disorders other than haemophilia A or B * Any major and/or orthopaedic surgery within one month prior to trial start * Advanced atherosclerotic disease (defined as known history of ischemic heart disease, ischemic stroke, etc.) * Clinical signs of renal dysfunction * Use of platelet inhibitors, including NSAIDs, one week prior to administration of trial drug * Use of non-prescribed opiate substances